In 2024, China will approve 48 innovative drugs for market, only lower than the 50 approved by the United States, ranking second in the world. In the first half of this year, the National Medical Products Administration approved the listing of 43 innovative drugs, a year-on-year increase of 59%. The explosive growth in the number of approved innovative drugs is the result of long-term policy guidance, technological accumulation, and capital cultivation in various regions to promote the transformation of the innovative drug industry from quantity to quality. In recent years, Beijing has deepened the opening up and reform of the entire industry chain in the field of medicine and health, and launched a series of national pioneering, first batch, and leading reform measures to create a favorable environment for the high-quality development of the industry. Gong Weimi, Deputy Director of the Beijing Municipal Commission of Science and Technology and the Zhongguancun Management Committee, introduced that the Beijing Municipal Commission of Science and Technology and the Zhongguancun Management Committee actively play the "dual leading" role of the science and technology innovation management department and the industry management department, and work together with the "three medical" departments to systematically plan and promote the further improvement and efficiency of Beijing's pharmaceutical and health industry from the aspects of innovation source, platform construction, research and review joint action, and full chain services. As one of the two pilot cities for optimizing the review and approval of clinical trials for innovative drugs, Beijing has released the "Several Measures to Support the High Quality Development of Innovative Medicine in Beijing (2025)" this year, introducing 32 new measures, including further strengthening the optimization of resource allocation, cultivating a high-quality innovation ecosystem, and promoting the high-quality development of innovative drugs and medical devices. As early as October 2019, the Chengdu Biomedical Industry Cluster was selected as one of the first national strategic emerging industry clusters. Recently, the Implementation Rules for Several Policies and Measures to Promote the High Quality Development of the Biomedical Industry in Chengdu were issued, proposing several types of special support policies around supporting drug and device research and development innovation, improving clinical research quality and efficiency, and supporting enterprise development and growth, providing precise support for various links of the biopharmaceutical industry. Chengdu has a good innovation ecosystem that supports technology research and development. Taking Chengdu Tianfu International Biotech City, jointly built by Chengdu High tech Zone and Shuangliu District, as an example, it is an important carrier of Chengdu's biopharmaceutical industry ecosystem. There are 108 new drugs under clinical research by biopharmaceutical enterprises in the park, and 63 Class 1 new drugs have entered the clinical stage. This year, the "wutong Plan" launched by Chengdu High tech Zone covers 9 categories and 47 directions, with a total of 102 sub services. It is the first list of full life cycle services for the pharmaceutical and health industry in China. Full chain innovation and research have entered the production workshop of Suzhou Xinda Biopharmaceutical Group located in Suzhou Biopharmaceutical Industry Park. The world's first and only approved dual target weight loss drug, Masidu Peptide, is busy in production. The new drug Masidu Peptide took only 16 months from application to market launch. ”Yin Zeyang, the production manager of Xinda Biopharmaceutical Enterprise, said that the birth of a new record for the company's new drug listing is due to Jiangsu's sound and comprehensive system and mechanism, and efforts to achieve breakthroughs and empowerment throughout the entire chain. For major innovative products such as Masidu Peptide, the competent department will establish a service team, organize experts to go deep into the production site of enterprises, conduct comprehensive evaluations from multiple dimensions such as process design, clean area layout, and risk control, guide enterprises to establish strict pollution control systems, and ultimately form personalized solutions. ”Shen Xiaojie, Director of the Administrative Approval Department of Jiangsu Provincial Drug Administration, said. According to the official website of the National Medical Products Administration, Chengdu holds 6 out of 40 domestically produced Class 1 innovative drugs approved for market in 2024. This year, this data will be refreshed. Behind the data refresh is Chengdu's "hard" strength in the field of innovative drugs - technological research and development. On May 29th of this year, the innovative drug deuterium enzalutamide produced by Haichuang Pharmaceutical Co., Ltd. was approved for market by the National Medical Products Administration. This is the first innovative drug launched by Haichuang Pharmaceutical. Currently, the company has 5 products in clinical trials and multiple products in preclinical research, forming a tiered product portfolio, "said Chen Yuanwei, Chairman of Haichuang Pharmaceutical Co., Ltd. Anchoring the "industry target" of innovative drugs, Jiangsu concentrates policy, funding, talent and other resources, increases research and development investment, strengthens innovation platforms, and gathers advantageous forces to carry out centralized research and development. Jiangsu has taken the lead in building seven national key laboratories in the field of biomedicine, and has also been approved to establish the only national technology innovation center in the field of biomedicine - the National Biopharmaceutical Technology Innovation Center. We focus on the key areas and key links of biopharmaceuticals, undertake tasks such as key technology research and development, public platform system construction, mechanism and system policy innovation, etc. Currently, through unveiling and leading the list, we have approved 66 projects, including 21 breakthrough key technologies. ”Wang Xie, Deputy Director of the National Biopharmaceutical Technology Innovation Center, said. Capital cultivation and support for innovative drug research and development is a high investment and long cycle "long-distance race". However, the evaluation system of the capital market often focuses more on the sales performance of pharmaceutical companies. How to adhere to scientific principles and make rational decisions based on clinical data under commercialization pressure is a common challenge faced by all innovative pharmaceutical companies. To solve this problem, Changping District in Beijing has established a diversified investment pattern of "government guidance+social capital participation". The 20 billion yuan Beijing Medical and Health Industry Investment Fund and the 1 billion yuan Life Valley Medical and Health Industry Fund have been successively launched, providing strong support for innovative pharmaceutical companies. Beijing Zhongguancun Life Science Park, located in Changping District, is a gathering area and transformation highland for cutting-edge technologies in cell and gene therapy in China, bringing together more than 40 key research and development enterprises and service institutions in related fields. Currently, over 20 companies' advanced treatment products have entered the clinical research stage. In recent years, Changping District has accelerated the layout of the "investment+clinical+incubation+park" four in one ecological circle, forming a complete industrial chain from basic research, pilot research and development, production and distribution to terminal medical care, and promoting more breakthroughs from 0 to 1, transformations from 1 to 10, and industrialization from 10 to 100. The relevant person in charge of Jiangsu Xiansheng Biopharmaceutical Co., Ltd. introduced that in order to achieve continuous breakthroughs in innovative drugs, the company has established a national key laboratory for the research and development of nerve and tumor drugs, focusing on anti-tumor and central nervous system diseases, and continuously investing in high-intensity research and development. On the basis of a cumulative R&D investment of 2 billion yuan in the first five years, the R&D expenses have increased to nearly 8 billion yuan in the following five years. With the dual support of policies and funding, various regions are accelerating the layout of cutting-edge fields and continuously improving innovation and industrial chains. Beijing has incorporated cutting-edge technologies such as brain computer interfaces, cell and gene therapy, and surgical robots into the scope of project-based services, connecting various service paths for enterprises such as policy support, investment empowerment, project-based lists, and foreign-funded research and development centers, forming a "service package" mechanism for precise services at the city and district levels. Since the beginning of this year, 13 innovative pharmaceutical and medical products have been approved for market in Beijing, ranking among the top in the country in terms of quantity. Since its establishment in 2006, Suzhou Biomedical Industry Park has focused on the core carrier of biomedicine, striving to create an incubation base for innovative drug research and development and high-end medical devices. Nowadays, the park has gathered more than 620 pharmaceutical innovation enterprises and over 35000 R&D talents, forming advantageous tracks in innovative drug research and development, high-end medical devices, biotechnology, and emerging therapies. (New Society)